Richard Finn

Richard Finn is the leading investigator in advanced hepatocellular carcinoma systemic therapy, having led the IMbrave150 trial that established atezolizumab plus bevacizumab as the first-line standard of care for unresectable HCC — displacing sorafenib after more than a decade as standard. He also led the REFLECT trial demonstrating non-inferiority of lenvatinib to sorafenib. His clinical trials research has generated multiple FDA approvals in HCC and he has contributed to NCCN and AASLD HCC treatment guidelines.